Congenital heart disease(CHD)has an estimated prevalence of 0.9%,with 0.3%requiring interventional or surgical intervention very early in life.Currently,CHD surgery tends to be performed at a younger age.The continued...Congenital heart disease(CHD)has an estimated prevalence of 0.9%,with 0.3%requiring interventional or surgical intervention very early in life.Currently,CHD surgery tends to be performed at a younger age.The continued management of the condition is dependent on postoperative care and rehabilitation since the success rate of surgery has significantly increased[1,2].According to American Heart Association guidelines published in 2012.展开更多
Congenital heart disease(CHD)has become the leading mortal cause for an infant from congenital abnormalities.Pulmonary artery hypertension(PAH)is one of the complications of CHD.[1]It has also been reported that upreg...Congenital heart disease(CHD)has become the leading mortal cause for an infant from congenital abnormalities.Pulmonary artery hypertension(PAH)is one of the complications of CHD.[1]It has also been reported that upregulation of microRNA-98(miR-98)could mediate the suppression of cardiac hypertrophy,which implies that miR-98 might play an important role in CHD.[2]In this study,the clinical data from hospitalized patients were retrospectively analyzed to identify if there is any evidence of diagnosis of circulating miR-98 on CHD patients with PAH.展开更多
文摘Congenital heart disease(CHD)has an estimated prevalence of 0.9%,with 0.3%requiring interventional or surgical intervention very early in life.Currently,CHD surgery tends to be performed at a younger age.The continued management of the condition is dependent on postoperative care and rehabilitation since the success rate of surgery has significantly increased[1,2].According to American Heart Association guidelines published in 2012.
文摘Congenital heart disease(CHD)has become the leading mortal cause for an infant from congenital abnormalities.Pulmonary artery hypertension(PAH)is one of the complications of CHD.[1]It has also been reported that upregulation of microRNA-98(miR-98)could mediate the suppression of cardiac hypertrophy,which implies that miR-98 might play an important role in CHD.[2]In this study,the clinical data from hospitalized patients were retrospectively analyzed to identify if there is any evidence of diagnosis of circulating miR-98 on CHD patients with PAH.
